Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center

Human Pathology

Volumn 42, Issue 11, 2011, Pages 1799-1803

  Lee, Thomas K ^a   Chaux, Alcides ^a   Karram, Sarah ^a   Miyamoto, Hiroshi ^a   Miller, Jeremy S ^a   Fajardo, Daniel A ^a   Epstein, Jonathan I ^a   Netto, George J ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Noninvasive urothelial carcinoma; Papillary urothelial neoplasm of low malignant potential; Prognosis; Progression rate; PUNLMP; Recurrence rate

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL OUTCOME; COHORT ANALYSIS; EVALUATION STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; PAPILLARY CARCINOMA; PAPILLARY UROTHELIAL NEOPLASM OF LOW MALIGNANT POTENTIAL; PRIMARY TUMOR; RECURRENCE RISK; TRANSITIONAL CELL CARCINOMA; BLADDER; BLADDER TUMOR; DISEASE COURSE; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84865063211     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.03.006     Document Type: Article

References (37)

1. Jones, T.D., Cheng, L., Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts. J Urol 175 (2006), 1995–2003.
2. Pan, C.C., Chang, Y.H., Chen, K.K., Yu, H.J., Sun, C.H., Ho, D.M., Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non–muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol 133 (2010), 788–795.
3. Miyamoto, H., Miller, J.S., Fajardo, D.A., Lee, T.K., Netto, G.J., Epstein, J.I., Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int 60 (2010), 1–8.
4. Epstein, J.I., Amin, M.B., Reuter, V.R., Mostofi, F.K., The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22 (1998), 1435–1448.
5. Edge, S.B., Byrd, D.R., Compton, C., Fritz, A.G., Greene, F.L., Trotti, A., AJCC Cancer Staging Manual, 2009, Springer, New York, 447–456.
6. Epstein, J.I., Diagnosis and classification of flat, papillary, and invasive urothelial carcinoma: the WHO/ISUP consensus. Int J Surg Pathol 18 (2010), 106S–111S.
7. Cheng, L., Neumann, R.M., Bostwick, D.G., Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer 86 (1999), 2102–2108.
8. Holmang, S., Hedelin, H., Anderstrom, C., Holmberg, E., Busch, C., Johansson, S.L., Recurrence and progression in low grade papillary urothelial tumors. J Urol 162 (1999), 702–707.
9. Fujii, Y., Kawakami, S., Koga, F., Nemoto, T., Kihara, K., Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int 92 (2003), 559–562.
10. Herr HW, Donat SM, Reuter VE. Management of low grade papillary bladder tumors. J Urol 2007; 178:1201, 5; [discussion 1205].
11. Alsheikh, A., Mohamedali, Z., Jones, E., Masterson, J., Gilks, C.B., Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/International Society of Urologic Pathology. Mod Pathol 14 (2001), 267–272.
12. Pich, A., Chiusa, L., Formiconi, A., et al. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer 95 (2002), 784–790.
13. Ramos, D., Navarro, S., Villamon, R., Gil-Salom, M., Llombart-Bosch, A., Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder. Cancer 97 (2003), 1876–1883.
14. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001;165:1124, 8; [discussion 1128-30].
15. Campbell, P.A., Conrad, R.J., Campbell, C.M., Nicol, D.L., MacTaggart, P., Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome. BJU Int 93 (2004), 1228–1231.
16. Yin, H., Leong, A.S., Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. Am J Clin Pathol 121 (2004), 679–687.
17. Desai, S., Lim, S.D., Jimenez, R.E., et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol 13 (2000), 1315–1323.
18. Oosterhuis, J.W., Schapers, R.F., Janssen-Heijnen, M.L., Pauwels, R.P., Newling, D.W., ten Kate, F., Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems. J Clin Pathol 55 (2002), 900–905.
19. Samaratunga, H., Makarov, D.V., Epstein, J.I., Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology 60 (2002), 315–319.
20. May, M., Brookman-Amissah, S., Roigas, J., et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 world health organisation classifications. Eur Urol 57 (2010), 850–858.
21. Murphy, W.M., Takezawa, K., Maruniak, N.A., Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J Urol 168 (2002), 968–972.
22. Yorukoglu, K., Tuna, B., Dikicioglu, E., et al. Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder. Virchows Arch 443 (2003), 734–740.
23. Bol, M.G., Baak, J.P., Buhr-Wildhagen, S., et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 169 (2003), 1291–1294.
24. Gonul, I.I., Poyraz, A., Unsal, C., Acar, C., Alkibay, T., Comparison of 1998 WHO/ISUP and 1973 WHO classifications for interobserver variability in grading of papillary urothelial neoplasms of the bladder. Pathological evaluation of 258 cases. Urol Int 78 (2007), 338–344.
25. Miyamoto, H., Brimo, F., Schultz, L., et al. Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Arch Pathol Lab Med 134 (2010), 1160–1163.
26. Epstein, J.I., Amin, M.B., Reuter, V.E., Papillary urothelial neoplasms and their precursors. Anonymous, (eds.) Biopsy interpretation of the bladder, 2010, Wolters Kluwer/Lippincott Williams & Wilkins Health, Philadelphia, 43–78.
27. Lane, Z., Epstein, J.I., Polypoid/papillary cystitis: a series of 41 cases misdiagnosed as papillary urothelial neoplasia. Am J Surg Pathol 32 (2008), 758–764.
28. Young, R.H., Tumor-like lesions of the urinary bladder. Mod Pathol 22:Suppl 2 (2009), S37–S52.
29. Barbisan, F., Santinelli, A., Mazzucchelli, R., et al. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer 112 (2008), 636–644.
30. Cina, S.J., Lancaster-Weiss, K.J., Lecksell, K., Epstein, J.I., Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia. Arch Pathol Lab Med 125 (2001), 646–651.
31. Barbisan, F., Mazzucchelli, R., Santinelli, A., et al. Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential. Int J Immunopathol Pharmacol 21 (2008), 615–623.
32. Montironi, R., Scarpelli, M., Lopez-Beltran, A., et al. Chromatin phenotype karyometry can predict recurrence in papillary urothelial neoplasms of low malignant potential. Cell Oncol 29 (2007), 47–58.
33. Scarpelli, M., Montironi, R., Tarquini, L.M., et al. Karyometry detects subvisual differences in chromatin organisation state between non-recurrent and recurrent papillary urothelial neoplasms of low malignant potential. J Clin Pathol 57 (2004), 1201–1207.
34. Knowles, M.A., Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 25 (2007), 581–593.
35. van Oers, J.M., Wild, P.J., Burger, M., et al. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol 52 (2007), 760–768.
36. van Rhijn, B.W., Lurkin, I., Radvanyi, F., Kirkels, W.J., van der Kwast, T.H., Zwarthoff, E.C., The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61 (2001), 1265–1268.
37. van Rhijn, B.W., van der Kwast, T.H., Vis, A.N., et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64 (2004), 1911–1914.